Zota Health Care
- Market cap
- ₹ 4,298 Cr.
- P/E
- 327x
- P/B
- 6.36x
- 52-week range
- 1,022 – 1,740
- ROE
- −15%
- ROCE
- −8%
- Dividend yield
- 0.1%
- Debt / equity
- 0.39
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE
About
Zota Health Care Limited is an India-based pharmaceutical company, which is engaged in the manufacturing and marketing of pharmaceutical products catering to domestic and international markets. It engages in manufacturing, marketing, and exporting a range of pharmaceutical, ayurvedic, nutraceutical, and over the counter (OTC) products. The Company’s business model comprises three verticals, namely Domestic, Exports, and Retail Pharmacy Chain. Its Domestic Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products. Its product portfolio offers over 4,000 therapeutic product categories such as generic, OTC products, allopathic, ayurvedic, and others. Its Retail Pharmacy Chain business operates under the Davaindia brand, which offers a range of private-label products that include pharmaceuticals, nutraceutical, OTC items, and ayurvedic treatments, with a focus on chronic disease management.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Zota Health Care against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)327 against a typical 34.3: pricier than most peers (1st = cheapest).210th of 220
- Sales growth+67.3% against a typical +15.6% from a year earlier.23rd of 197
- Share price, 3 months+2.2% against a typical −0.5%.84th of 200
- Size₹ 4,298.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).56th of 199
Latest announcements
Exchange filings and their impact on the company.
- 28 Oct 2026Outcome of Board MeetingMedium impactNegativeStrong revenue growth continues but losses are running at FY26 full-year level in just H1, keeping earnings negative.
On October 28, 2026 the board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing discloses subsidiaries revenue of Rs 139.1 cr in Q2 and Rs 254.6 cr in H1, with net loss of Rs 28.8 cr in Q2 and Rs 67.8 cr in H1. It points to continued strong sales growth but persistent large losses, with H1 losses already around last full-year level.
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 17 Dec 2025 | QIP | Board approved | ₹ 349.99 Cr. | ₹ 1,535 | −17.26% |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 28 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 13 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 22 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 4 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 17 Oct 2025 | Financial Results/Other business matters | To consider and approve the financial results for the quarter and half year ended September 30, 2025 and other business matters |
| 4 Sep 2025 | Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| 8 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 | 129 | 143 | 163 | 174 |
| Expenses | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 | 123 | 143 | 154 | 185 |
| Operating Profit | 4 | 3 | −1 | −1 | −1 | −6 | 2 | 4 | 6 | 0 | 9 | −12 |
| OPM % | 10% | 7% | −3% | −2.2% | −1.3% | −8% | 2.5% | 3.8% | 4.9% | −0.3% | 5% | −7% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | −3 | 2 |
| Interest | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 | 5 | 5 | 6 |
| Depreciation | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 | 19 | 22 | 27 | 28 |
| Profit before tax | −1 | −3 | −10 | −12 | −13 | −18 | −14 | −13 | −14 | −26 | −26 | −44 |
| Tax % | 49% | 7% | −27% | 5% | −4% | 2% | −10% | 5% | 13% | 14% | −45% | 1% |
| Net Profit | −2 | −3 | −7 | −13 | −12 | −19 | −13 | −14 | −16 | −30 | −14 | −44 |
| EPS in Rs | −0.64 | −1.14 | −2.68 | −4.79 | −4.41 | −6.78 | −4.5 | −4.81 | −5.2 | −8.73 | −4.09 | −12.58 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 38%
- 3 Years
- 57%
- TTM
- 79%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −69%
- 10 Years
- —
- 5 Years
- 27%
- 3 Years
- 34%
- TTM
- —
- 10 Years
- —
- 5 Years
- −16%
- 3 Years
- −20%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Zota Health Care | ₹ 1,270.00 | ₹ 4,298 Cr. | 327x | 6.4x | −15% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
Management
- Sujit Paul
- Group Chief Executive Officer
- Viral A. Mandviwala
- Chief Financial Officer
- Ashvin Bhagavanbhai Variya
- Compliance Officer, Company Secretary
- Moxesh Ketanbhai Zota
- Managing Director
- Laxmi Kant Sharma
- Executive Director
- Himanshu Muktilal Zota
- Whole-time Director
- Kamlesh Rajanikant Zota
- Whole-Time Director
- Viren Manukant Zota
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.